Search

A recent study conducted by researchers from the Michael E. DeBakey Department of Surgery has developed a liquid biopsy test for pediatric liver cancer. The aim of the study was to create a less invasive method that provides real-time information about tumor response to therapy. The researchers utilized indocyanine green (ICG), a far-red fluorescent dye, to specifically detect and quantify circulating tumor cells (CTCs) in the blood of pediatric patients with liver cancer. The test showed promising results in identifying liver tumor cells and correlating CTC burden with patient responses to therapy. [Extracted from the article]

A recent study conducted by the National Cancer Institute (NCI) in Frederick, Maryland, has explored the development of iodinated indocyanine green analogs as a targeted therapy for liver cancer. Liver cancer is a leading cause of cancer-related deaths globally, and there is a need for novel therapies to address this issue. The researchers designed and synthesized a series of iodinated indocyanine green analogs, which showed promising results in targeting liver cancer in vitro and in vivo. This study provides valuable insights into the potential of indocyanine green-based targeted radiopharmaceutical therapy for liver cancer. [Extracted from the article]

A recent study conducted by researchers at Baylor College of Medicine has shown promising results for the treatment of hepatoblastoma (HB), the most common liver cancer in children. The researchers developed a novel combination therapy that included an inhibitor of the enzyme histone deacetylase (HDAC), which was found to be effective in eliminating cancer cells. The therapy was tested in animal models and showed a significant decrease in tumor volume and tumor marker levels. These findings suggest that the combination therapy may be a promising option for patients with high-risk, relapsed, or refractory HB. [Extracted from the article]

A recent study conducted at the Dan L. Duncan Cancer Center focused on hepatoblastoma (HB), the most common primary hepatic malignancy in childhood. The study aimed to identify risk factors for relapsed HB and predictors of survival. The researchers found that patients with relapsed HB had a lower overall survival rate compared to those without relapse. They also discovered that PRETEXT IV staging was an independent predictor of relapsed disease, and surgical resection was an important component of multimodal therapy for relapsed HB. The study provides valuable insights into the management of hepatoblastoma and highlights the need for further research in this area. [Extracted from the article]